BioCision LLC, the CoolRack™ company, today announced that it has entered into an agreement with Therapak Corporation for the distribution of BioCision’s products into the clinical market. The deal marks BioCision’s first distribution agreement for the clinical market and expands its access to clinical settings across the United States and Europe.
“We are excited about our partnership with Therapak and the opportunities it brings to expand our business in the clinical market,” said BioCision CEO Rolf Ehrhardt, M.D., PhD. “Clinical scientists are increasingly turning to our inexpensive and easy-to-use laboratory tools to help them standardize cooling, freezing and thawing procedures of their patient samples across multiple sites - ultimately ensuring more accurate and reproducible data.”
Therapak is a leading supplier of diagnostic test kits used by hospitals, physicians, laboratories and pharmaceutical companies worldwide. The company provides a wide range of custom specimen collection and transport kits designed for direct distribution to collection sites and return shipment to a clinical testing laboratory. BioCision’s CoolRack products are available through Therapak’s online catalog at http://www.therapak.com/catalog/coolracks.
”Therapak’s collaboration with BioCision will provide both parties with opportunities to penetrate clinical business segments that are in need of such specialized products,” said Therapak President Todd M Gates. “This partnership builds on Therapak’s continuous efforts to improve the quality of the sample collection and processing workflow through its offerings of customized sample collection kits to novel temperature management systems offered through BioCision.”
BioCision is a leading maker of portable benchtop tools for temperature sensitive biomedical samples and experiments. Its highly thermo-conductive CoolRack™ enables easy sample cooling, snap freezing, heating and thawing. Along with CoolRacks, BioCision’s portable benchtop coolers, portable benchtop freezers, and thermally conductive platforms bring portability and all-day temperature control to the benchtop, increasing reproducibility and accuracy in scientific experiments.
Since BioCision’s founding in 2007, the company has commercialized nearly 40 products now used by leading pharmaceutical and biotechnology companies, contract research organizations, and academic and healthcare institutions worldwide.
Study reveals how cancer cells evade chemotherapy in low-glucose environments